Impact Dashboard

SPARC supports Molecular Tumor Boards (MTBs) with advanced diagnostic workflows and AI-enabled tools.

These improvements have led to:

• More structured and consistent clinical case discussions
• Increased confidence among clinicians when recommending personalised therapies
• More timely interpretation of genomic and liquid biopsy findings
• Better multidisciplinary alignment between oncologists, pathologists, molecular biologists, radiologists, genetic counsellors, and bioinformaticians

AI tools incorporated into MTB processes assist with variant interpretation, literature evidence retrieval, and prioritisation of actionable findings, helping specialists navigate increasingly complex datasets.

SPARC contributes to a stronger oncology workforce by providing:

• Comprehensive training materials tailored to clinicians, nurses, researchers, genetic counsellors, and laboratory professionals
• E-learning modules covering genomics, liquid biopsy, AI-assisted diagnostics, data ethics, and patient communication
• Twinning activities connecting high-capacity centres with emerging centres
• Workshops, seminars, and expert exchanges supporting continuous professional development

The training ecosystem addresses both foundational knowledge and advanced technical competencies, ensuring that experts at all levels can work with modern precision-oncology tools.

SPARC places strong emphasis on ensuring equitable access to personalised cancer medicine across Europe.

Key improvements include:

• Wider geographic availability of advanced diagnostics such as NGS and liquid biopsy
• More streamlined patient pathways reducing delays from suspicion to diagnosis to treatment
• Patient education resources enabling individuals to better understand test results and therapeutic options
• Engagement with patient organisations to co-design communication materials and ensure inclusiveness

These efforts help mitigate disparities related to geography, digital readiness, socioeconomic conditions, or hospital capacity.

SPARC’s data architecture enhances the ability of institutions to share, harmonise, and interpret clinical and genomic information.

Advances include:

• FAIR-aligned data models that ensure data remains findable, accessible, interoperable, and reusable
• Unified standards for handling genomics, imaging, pathology, and clinical metadata
• GDPR-compliant governance frameworks and secure pipelines
• Clinical dashboards that visualise patient journeys, diagnostic findings, and MTB recommendations

This digital backbone supports multi-country collaboration, research acceleration, and better-informed clinical decisions.

The project contributes to long-term European goals by:

• Providing evidence to support national and EU-level cancer policies
• Developing sustainability frameworks that help countries integrate personalised medicine into routine care
• Mapping equity gaps and proposing practical solutions
• Supporting alignment with the Europe’s Beating Cancer Plan, EU Cancer Mission, and EU4Health priorities

The dashboard highlights progress not just in clinical improvements but also in broader system strengthening.